Global human papillomavirus vaccine market is anticipated to observe impressive growth during the forecast period, 2024-2028. Growing incidences of Human Papillomavirus Virus-related diseases, along with the rise in initiatives by government and private organizations to spread awareness related to human papillomavirus worldwide are augmenting the growth of the market. Human papillomavirus infection is the most common sexually transmitted contamination caused by Human Papillomavirus Virus-related cancers such as cervical, penile, and genital cancer. Human papillomavirus vaccines are immunizations that protects from certain type of human papillomavirus. It protects against either two, four or nine kinds of Human Papillomavirus Virus. The factors supporting the market’s growth are, the increasing research for the development of therapeutic vaccine, large number of clinical trials, increasing awareness and government investments, growing need to reduce Human Papillomavirus Virus infections, among others. According to clinical trials.gov, as of November 2022, around 394 clinical studies are in different phases of development related to human papillomavirus vaccine across the globe.

Increasing Cases of Human Papillomavirus Diseases

Upsurge in the cases of Human Papillomavirus related diseases in different organs such as anal, oropharynx, and genital parts has significantly risen the demand for Human Papillomavirus vaccines, thereby creating lucrative opportunities for the market growth. There are just three types of vaccines in the market: bivalent, tetravalent, and nonvalent. All the three vaccines are highly effective in avoiding infection with both virus types 16 and 18, which are liable for curing 70% of cervical cancer cases. According to the Centers for Disease Control and Prevention (CDC), in United States, human papillomavirus is the most common sexually transmitted infection. Over 70% of vulvar and vaginal diseases, 60% of penile malignant growths, and 90% of anal cancer and cervical tumors are caused because of Human Papillomavirus. Moreover, in women, cervical cancer is very common among age between 9 to 30, which spur the need for HPV vaccine. For instance, according to the WHO, in 2017, cervical cancer was liable for over 2,50,000 deaths of women globally and 85% of these deaths occured in developing countries.

Increasing Initiatives by Government & Private Organizations

Over the past few years, governments of different nations and private organizations are taking several steps to create awareness among the population with regards to papillomavirus among the population, thereby driving the growth of the human papillomavirus vaccine market.  This has in turn increased the research and development activities and product launched related to human papillomavirus vaccine. For instance, recently, India launched the first quadrivalent human papillomavirus vaccine (qHPV) against cervical cancer. Also, Profectus Biosciences, Inc., is in process to develop GeneVax prime/VesiculoVax, a therapeutic vaccine for HPV. The vaccine is believed to be effective against seven Human Pappilomavirus kinds. Furthermore, organizations, especially UNICEF, have made efforts to improve vaccine acceptance over the years. The impact of the Pan American Health Organization (PAHO) revolving fund and UNICEF supply division permits vaccinations to be acquired at lower prices for diverse nations.


Download Free Sample Report

Market Segmentation

Global human papillomavirus vaccine market is segmented into valence, disease indication, distribution channel, and company. Based on valence, the market is divided into bivalent, quadrivalent, nonvalent, and others. Based on disease indication, the market is categorized into cervical cancer, anal cancer, vaginal cancer, penile cancer, vulvar cancer, and others. Based on distribution channel, the market is segmented into hospitals & clinics, governmental & non-governmental organizations, public & private alliances, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising prevalence of human papillomavirus related diseases and better healthcare infrastructure in the country.

Market Players

Serum Institute of India Pvt. Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Novartis AG, Inovio Pharmaceuticals, Inc., Xenetic Biosciences, Inc., Sanofi SA, and Bharat Biotech International Limited are some of the leading companies operating in the market.

Attribute

Details

Base Year

2022

Historic Data

2018 – 2021

Estimated Year

2023

Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million, CAGR for 2018-2022 and 2023-2028

Report coverage

Revenue forecast, Company share, Competitive landscape, Growth factors, and Trends

Segments covered

·         Valence

·         Disease Indication

·         Distribution Channel

·         Company

·         Region

Regional scope

North America; Asia Pacific; Europe & CIS; South America; Middle East & Africa

Country scope

United States; Canada; Mexico; China; India; Japan; South Korea; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; South Africa; UAE; Saudi Arabia; South Africa

Key companies profiled

Serum Institute of India Pvt. Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Novartis AG, Inovio Pharmaceuticals, Inc., Xenetic Biosciences, Inc., Sanofi SA, and Bharat Biotech International Limited

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Report Scope:

In this report, global human papillomavirus vaccine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

·         Human Papillomavirus Vaccine Market, By Valence:

    • Bivalent
    • Quadrivalent
    • Nonvalent
    • Others    

·         Human Papillomavirus Vaccine Market, By Disease Indication:

    • Cervical Cancer
    • Anal Cancer
    • Vaginal Cancer
    • Penile Cancer
    • Vulvar Cancer
    • Others

·         Human Papillomavirus Vaccine Market, By Distribution Channel:

    • Hospitals & Clinics
    • Governmental & Non-Governmental Organizations
    • Public & Private Alliances
    • Others

·         Human Papillomavirus Vaccine Market, By Region:

    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • United Kingdom
      • Spain
      • Italy
    • Asia-Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Human Papillomavirus Vaccine Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Human Papillomavirus Vaccine Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Clinical Trial Analysis

5.1.  Ongoing Clinical Trials

5.2.  Completed Clinical Trials

5.3.  Terminated Clinical Trials

5.4.  Breakdown of Pipeline, By Development Phase

5.5.  Breakdown of Pipeline, By Status

5.6.  Breakdown of Pipeline, By Study Application

5.7.  Breakdown of Pipeline, By Region

5.8.  Clinical Trials Heat Map

6.    Patent Analysis

7.    Global Human Papillomavirus Vaccine Market Outlook

7.1.  Market Size & Forecast

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Valence (Bivalent, Quadrivalent, Nonvalent, Others)

7.2.2.     By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others)

7.2.3.     By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others)

7.2.4.     By Region

7.2.5.     By Company (2022)

7.3.  Market Map

7.3.1.     By Valence

7.3.2.     By Disease Indication

7.3.3.     By Distribution Channel

7.3.4.     By Region

8.    North America Human Papillomavirus Vaccine Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Valence

8.2.2.     By Disease Indication

8.2.3.     By Distribution Channel

8.2.4.     By Country

8.3.  North America: Country Analysis

8.3.1.     United States Human Papillomavirus Vaccine Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Valence

8.3.1.2.2.             By Disease Indication

8.3.1.2.3.             By Distribution Channel

8.3.2.     Mexico Human Papillomavirus Vaccine Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Valence

8.3.2.2.2.             By Disease Indication

8.3.2.2.3.             By Distribution Channel

8.3.3.     Canada Human Papillomavirus Vaccine Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Valence

8.3.3.2.2.             By Disease Indication

8.3.3.2.3.             By Distribution Channel

9.    Europe Human Papillomavirus Vaccine Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Valence

9.2.2.     By Disease Indication

9.2.3.     By Distribution Channel

9.2.4.     By Country

9.3.  Europe: Country Analysis

9.3.1.     France Human Papillomavirus Vaccine Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Valence

9.3.1.2.2.             By Disease Indication

9.3.1.2.3.             By Distribution Channel

9.3.2.     Germany Human Papillomavirus Vaccine Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Valence

9.3.2.2.2.             By Disease Indication

9.3.2.2.3.             By Distribution Channel

9.3.3.     United Kingdom Human Papillomavirus Vaccine Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Valence

9.3.3.2.2.             By Disease Indication

9.3.3.2.3.             By Distribution Channel

9.3.4.     Italy Human Papillomavirus Vaccine Market Outlook

9.3.4.1.         Market Size & Forecast

9.3.4.1.1.             By Value

9.3.4.2.         Market Share & Forecast

9.3.4.2.1.             By Valence

9.3.4.2.2.             By Disease Indication

9.3.4.2.3.             By Distribution Channel

9.3.5.     Spain Human Papillomavirus Vaccine Market Outlook

9.3.5.1.         Market Size & Forecast

9.3.5.1.1.             By Value

9.3.5.2.         Market Share & Forecast

9.3.5.2.1.             By Valence

9.3.5.2.2.             By Disease Indication

9.3.5.2.3.             By Distribution Channel

10.  Asia-Pacific Human Papillomavirus Vaccine Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Valence

10.2.2.  By Disease Indication

10.2.3.  By Distribution Channel

10.2.4.  By Country

10.3.              Asia-Pacific: Country Analysis

10.3.1.  China Human Papillomavirus Vaccine Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Valence

10.3.1.2.2.           By Disease Indication

10.3.1.2.3.           By Distribution Channel

10.3.2.  India Human Papillomavirus Vaccine Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Valence

10.3.2.2.2.           By Disease Indication

10.3.2.2.3.           By Distribution Channel

10.3.3.  Japan Human Papillomavirus Vaccine Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Valence

10.3.3.2.2.           By Disease Indication

10.3.3.2.3.           By Distribution Channel

10.3.4.  South Korea Human Papillomavirus Vaccine Market Outlook

10.3.4.1.      Market Size & Forecast

10.3.4.1.1.           By Value

10.3.4.2.      Market Share & Forecast

10.3.4.2.1.           By Valence

10.3.4.2.2.           By Disease Indication

10.3.4.2.3.           By Distribution Channel

10.3.5.  Australia Human Papillomavirus Vaccine Market Outlook

10.3.5.1.      Market Size & Forecast

10.3.5.1.1.           By Value

10.3.5.2.      Market Share & Forecast

10.3.5.2.1.           By Valence

10.3.5.2.2.           By Disease Indication

10.3.5.2.3.           By Distribution Channel

11.  South America Human Papillomavirus Vaccine Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Valence

11.2.2.  By Disease Indication

11.2.3.  By Distribution Channel

11.2.4.  By Country

11.3.              South America: Country Analysis

11.3.1.  Brazil Human Papillomavirus Vaccine Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Valence

11.3.1.2.2.           By Disease Indication

11.3.1.2.3.           By Distribution Channel

11.3.2.  Argentina Human Papillomavirus Vaccine Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Valence

11.3.2.2.2.           By Disease Indication

11.3.2.2.3.           By Distribution Channel

11.3.3.  Colombia Human Papillomavirus Vaccine Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Valence

11.3.3.2.2.           By Disease Indication

11.3.3.2.3.           By Distribution Channel

12.  Middle East and Africa Human Papillomavirus Vaccine Market Outlook

12.1.              Market Size & Forecast

12.1.1.  By Value

12.2.              Market Share & Forecast

12.2.1.  By Valence

12.2.2.  By Disease Indication

12.2.3.  By Distribution Channel

12.2.4.  By Country

12.3.              MEA: Country Analysis

12.3.1.  South Africa Human Papillomavirus Vaccine Market Outlook

12.3.1.1.      Market Size & Forecast

12.3.1.1.1.           By Value

12.3.1.2.      Market Share & Forecast

12.3.1.2.1.           By Valence

12.3.1.2.2.           By Disease Indication

12.3.1.2.3.           By Distribution Channel

12.3.2.  Saudi Arabia Human Papillomavirus Vaccine Market Outlook

12.3.2.1.      Market Size & Forecast

12.3.2.1.1.           By Value

12.3.2.2.      Market Share & Forecast

12.3.2.2.1.           By Valence

12.3.2.2.2.           By Disease Indication

12.3.2.2.3.           By Distribution Channel

12.3.3.  UAE Human Papillomavirus Vaccine Market Outlook

12.3.3.1.      Market Size & Forecast

12.3.3.1.1.           By Value

12.3.3.2.      Market Share & Forecast

12.3.3.2.1.           By Valence

12.3.3.2.2.           By Disease Indication

12.3.3.2.3.           By Distribution Channel

13.  Market Dynamics

13.1.              Drivers

13.2.              Challenges

14.  Market Trends & Developments

14.1.              Recent Developments

14.2.              Mergers & Acquisitions

14.3.              Product Launches

15.  Competitive Landscape

15.1.              Business Overview

15.2.              Company Snapshot

15.3.              Products & Services

15.4.              Financials (As reported)

15.5.              Recent Developments

15.6.              SWOT Analysis

15.6.1.  Serum Institute of India Pvt. Ltd.

15.6.2.  GlaxoSmithKline Plc.

15.6.3.  Johnson & Johnson

15.6.4.  Merck & Co., Inc.

15.6.5.  AstraZeneca Plc

15.6.6.  Novartis AG

15.6.7.  Inovio Pharmaceuticals, Inc.

15.6.8.  Xenetic Biosciences, Inc.

15.6.9.  Sanofi SA

15.6.10.                Bharat Biotech International Limited

Strategic Recommendations

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com